Colombia’s Ministry of Health declared public interest grounds to pursue mandatory licensing of Gilead’s sofosbuvir-based hepatitis C patents, transferring the process to the competition authority for a final determination.

PHARMA · INFECTIOUS DISEASES & VACCINES · SEPTEMBER 12, 2026 · LATIN AMERICA
Patent exclusivity over some of the most effective treatments for hepatitis C infection now faces a formal legal challenge in Colombia. On 16 March 2026, the Ministerio de Salud y Protección Social (the Ministry) signed Resolution 453 de 2026, declaring the existence of public interest grounds to subject several patents covering direct-acting antiviral (DAA) combinations to mandatory licensing — a step that, if completed, would open the door to generic versions of therapies that have remained under Gilead Sciences’ exclusivity for years.
The resolution targets patents held by Gilead Sciences, Inc. and Gilead Pharmasset LLC covering two fixed-dose combinations: sofosbuvir + velpatasvir and sofosbuvir + velpatasvir + voxilaprevir. According to the resolution and reporting by Infobae, the affected patents carry expiry dates of 2028, 2032, and 2033 — meaning the commercial exposure, if a licence is ultimately granted, extends well over a decade from today. The petition that initiated the process was filed by Fundación Ifarma, a Colombian health-policy and access organisation.
A declaration is not yet a licence
The procedural architecture matters here. Resolution 453 does not itself grant a mandatory licence. Per the Ministry’s own announcement, the declaration concludes the Ministry’s administrative phase and transfers the process to the Superintendencia de Industria y Comercio (SIC), Colombia’s industrial-property authority, which must conduct its own proceeding before any licence is issued. Gilead retains its exclusivity until the SIC acts — and retains a second procedural window to contest the terms of any proposed licence at that stage. The Ministry is required to formally notify Gilead Sciences and Gilead Pharmasset as patent holders, as well as Fundación Ifarma as petitioner and any other interested third parties, per the resolution.
Colombia’s regulatory framework for this type of action draws on Andean Community Decision 486 of 2000, which governs the general patent regime, and on Decree 1074 of 2015 — the single regulatory decree for the commerce and industry sector — as modified by Decree 670 of 2017. The Comisión Nacional de Precios de Medicamentos y Dispositivos Médicos (the National Medicines Price Commission), through Circular 03 of 2016, established a parallel price-regulation methodology applicable when a public-interest declaration has been made, giving the government a pricing lever that does not require a full licence grant. Whether the Ministry or the SIC pursues that route, or presses for a full licence, has not been publicly disclosed.
A procurement record that frames the stakes
Colombia has operated a centralised purchasing mechanism for hepatitis C DAAs since Resolution 1692 of 2017, which established criteria for centralised acquisition through the Pan American Health Organization (PAHO) Strategic Fund — a regional procurement vehicle that pools demand to reduce unit costs. In September 2024, the Ministry and ADRES, the administrator of Colombia’s General Social Security Health System resources, announced the acquisition of 2,610 hepatitis C treatments at a total cost of COP 39,605 million pesos, according to a Ministry press release — a volume representing a 30.5 percent increase over the prior purchase order, per the same source. Those treatments were distributed to 14 Entidades Promotoras de Salud (EPS), the managed-care organisations that administer coverage under Colombia’s Sistema General de Seguridad Social en Salud (SGSSS).
The centralised model has allowed Colombia to acquire DAAs at prices below commercial list rates, but the Ministry’s own 2017 implementation documents noted that the high cost of these therapies continued to strain system sustainability. A 2016 Ministry presentation estimated Colombia’s hepatitis C virus (HCV) prevalence at between 0.79 percent and 0.85 percent of the population — equivalent to between 382,000 and 409,139 people at that time, according to Ministry data drawing on SIVIGILA surveillance records and FOSYGA reimbursement data. The gap between that estimated burden and the number of people actually receiving treatment has been the stated rationale for successive access interventions, including the current mandatory-licensing push.
Most published figures on Colombia’s hepatitis C treatment volumes and costs trace to Ministry of Health sources, which have a direct institutional interest in the policy outcome. No independent audit of those figures has been cited in the available record.
The strongest counterargument to the thesis that mandatory licensing will materially expand access is operational, not legal. Even if the SIC grants a licence, a generic manufacturer must be identified, production capacity secured, and the product registered with INVIMA, Colombia’s national food and drug surveillance institute. Colombia’s existing centralised-procurement infrastructure — the PAHO Strategic Fund channel and the MIPRES prescription-tracking platform and ACMED inventory-monitoring system, both mandated under Circular 12 of 2026 — was built around a small number of known suppliers. Integrating a new generic entrant into that logistics chain is not automatic. The Ministry’s April 2026 Circular 12 de 2026 focused specifically on tightening traceability and inventory control for DAAs acquired through centralised purchase, signalling that supply-chain discipline, not just price, remains an active concern.
Gilead’s position in this proceeding has not been publicly stated in the available record, and no executive comment has been published. PhRMA, the Washington-based pharmaceutical industry association, filed comments in January 2018 opposing an earlier Ministry resolution — Resolution 5246 of 2017 — that had initiated a broader public-interest review of DAA patents, arguing that the resolution was procedurally deficient and inconsistent with Colombia’s international trade obligations. That earlier proceeding did not result in a licence; Resolution 453 of 2026 represents a narrower, patent-specific action that the Ministry appears to have structured to address the procedural objections raised at that time. Whether Gilead or PhRMA will mount a comparable challenge to Resolution 453 has not been disclosed.
What to Watch
- The SIC’s timeline for opening and concluding its mandatory-licensing proceeding — no deadline has been publicly announced.
- Whether the Ministry invokes Circular 03 of 2016’s price-regulation mechanism as an alternative or complement to a full licence grant.
- INVIMA registration activity from any generic manufacturer seeking to enter the Colombian DAA market ahead of or following an SIC determination.
The deeper signal is structural: Colombia is using the mandatory-licensing pathway not as a one-off emergency measure but as a policy instrument layered on top of an already-functioning centralised procurement system. If the SIC grants a licence, the question for the system is not whether cheaper DAAs become available in principle, but whether the existing EPS distribution and MIPRES tracking infrastructure can absorb a new supplier class without the supply-chain disruptions that have historically delayed access gains in similar markets.







